To the Editor: As emphasized by Dr Koreth and colleagues,1 the assessment of allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission requires controlled prospective clinical trials. In their meta-analysis, the authors evaluated trials in which treatment assignment was based on the presence or absence of an HLA-matched donor. Although the authors recognized the inclusion of patients having no siblings as a source of bias,2 they did not select their group for analysis accordingly.
Büchner T. Donor Availability and Clinical Trials for Allogeneic Stem Cell Transplantation. JAMA. 2009;302(15):1647-1648. doi:10.1001/jama.2009.1485